Lee, J.; Liu, H.; Pearson, T.; Iwase, T.; Fuson, J.; Lalani, A.S.; Eli, L.D.; Diala, I.; Tripathy, D.; Lim, B.;
et al. PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening. Biomedicines 2021, 9, 740.
https://doi.org/10.3390/biomedicines9070740
AMA Style
Lee J, Liu H, Pearson T, Iwase T, Fuson J, Lalani AS, Eli LD, Diala I, Tripathy D, Lim B,
et al. PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening. Biomedicines. 2021; 9(7):740.
https://doi.org/10.3390/biomedicines9070740
Chicago/Turabian Style
Lee, Jangsoon, Huey Liu, Troy Pearson, Toshiaki Iwase, Jon Fuson, Alshad S. Lalani, Lisa D. Eli, Irmina Diala, Debu Tripathy, Bora Lim,
and et al. 2021. "PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening" Biomedicines 9, no. 7: 740.
https://doi.org/10.3390/biomedicines9070740
APA Style
Lee, J., Liu, H., Pearson, T., Iwase, T., Fuson, J., Lalani, A. S., Eli, L. D., Diala, I., Tripathy, D., Lim, B., & Ueno, N. T.
(2021). PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening. Biomedicines, 9(7), 740.
https://doi.org/10.3390/biomedicines9070740